$AZN,...AstraZeneca's tremelimumab an Orphan Drug for mesothelioma
The FDA designates AstraZeneca's (AZN +1.4%) anti-CTLA-4 monoclonal antibody, tremelimumab, an Orphan Drug for the treatment of malignant mesothelioma, an aggressive cancer affecting the lining of the lungs and abdomen that is associated with asbestos exposure.
Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
Market Data 
Markets 
AI
